JP2009532369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532369A5 JP2009532369A5 JP2009503084A JP2009503084A JP2009532369A5 JP 2009532369 A5 JP2009532369 A5 JP 2009532369A5 JP 2009503084 A JP2009503084 A JP 2009503084A JP 2009503084 A JP2009503084 A JP 2009503084A JP 2009532369 A5 JP2009532369 A5 JP 2009532369A5
- Authority
- JP
- Japan
- Prior art keywords
- neuron
- disease
- composition
- neurons
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002569 neuron Anatomy 0.000 claims 29
- 230000006378 damage Effects 0.000 claims 10
- 238000000034 method Methods 0.000 claims 7
- 102100021253 Antileukoproteinase Human genes 0.000 claims 6
- 101000615334 Homo sapiens Antileukoproteinase Proteins 0.000 claims 6
- 101000879712 Streptomyces lividans Protease inhibitor Proteins 0.000 claims 6
- 208000027418 Wounds and injury Diseases 0.000 claims 6
- 208000014674 injury Diseases 0.000 claims 6
- 210000003050 axon Anatomy 0.000 claims 5
- 210000005056 cell body Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 230000003376 axonal effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000000944 nerve tissue Anatomy 0.000 claims 4
- 230000000638 stimulation Effects 0.000 claims 4
- 230000000451 tissue damage Effects 0.000 claims 4
- 231100000827 tissue damage Toxicity 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 3
- 210000002161 motor neuron Anatomy 0.000 claims 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims 3
- 210000000278 spinal cord Anatomy 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010023497 kuru Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims 1
- 102000006386 Myelin Proteins Human genes 0.000 claims 1
- 108010083674 Myelin Proteins Proteins 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 102100023132 Transcription factor Jun Human genes 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000005012 myelin Anatomy 0.000 claims 1
- 210000003625 skull Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78802106P | 2006-03-30 | 2006-03-30 | |
| US78792706P | 2006-03-31 | 2006-03-31 | |
| PCT/US2007/008270 WO2007117440A2 (en) | 2006-03-30 | 2007-03-30 | Stimulation of neuron regeneration by secretory leukocyte protease inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009532369A JP2009532369A (ja) | 2009-09-10 |
| JP2009532369A5 true JP2009532369A5 (enExample) | 2010-05-20 |
Family
ID=38542264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503084A Pending JP2009532369A (ja) | 2006-03-30 | 2007-03-30 | 分泌性白血球プロテアーゼインヒビターによる神経再生の刺激 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8367615B2 (enExample) |
| EP (1) | EP2012819A2 (enExample) |
| JP (1) | JP2009532369A (enExample) |
| CA (1) | CA2647246C (enExample) |
| WO (1) | WO2007117440A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2639526C2 (ru) * | 2011-06-28 | 2017-12-21 | ИНХИБРКС ЭлЭлСи | Слитые полипептиды, содержащие домен wap, и способы их применения |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| SMT201900520T1 (it) | 2011-06-28 | 2019-11-13 | Inhibrx Lp | Polipeptidi di fusione serpinici e relativi metodi d'uso |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650148A (en) | 1988-12-15 | 1997-07-22 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system |
| US6017880A (en) * | 1994-03-09 | 2000-01-25 | Amgen Inc. | Inhibition of retrovirus infection |
| US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
| JPH10501686A (ja) | 1994-04-13 | 1998-02-17 | ザ ロックフェラー ユニヴァーシティ | 神経系の細胞へのｄｎａのａａｖ仲介送達 |
| US6096716A (en) | 1994-12-12 | 2000-08-01 | The Board Of Regents, The University Of Texas System | Liposome-mediated transfection of central nervous system cells |
| US5932542A (en) | 1995-06-27 | 1999-08-03 | Research Foundation Of Cuny, Hunter College | Composition and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof |
| AU1979897A (en) | 1996-03-04 | 1997-09-22 | University Of Medicine And Dentistry Of New Jersey | Genetically engineered primary oligodendrocytes for transplantation-mediated gene delivery in the central nervous system |
| US6210664B1 (en) | 1996-04-08 | 2001-04-03 | New York University Medical Center | Method for gene transfer to the central nervous system |
| US7544511B2 (en) | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| GB9816775D0 (en) | 1998-07-31 | 1998-09-30 | Efstathiou Stacey | Herpesviral vectors for gene delivery |
| AU6078500A (en) * | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
| DE60137414D1 (de) | 2000-05-05 | 2009-03-05 | Univ City | Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese |
| JP4426179B2 (ja) * | 2000-12-18 | 2010-03-03 | アライバ ファーマシューティカルズ，インコーポレイティド | 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用 |
| WO2003016539A1 (en) | 2001-03-13 | 2003-02-27 | Thomas Jefferson University | Retroviral vectors for gene transfer into neuronal cells |
| US20090232910A1 (en) * | 2004-07-22 | 2009-09-17 | Duke University | Biomarkers and therapeutics targets for cognitive decline |
-
2007
- 2007-03-30 EP EP07774572A patent/EP2012819A2/en not_active Withdrawn
- 2007-03-30 US US12/225,639 patent/US8367615B2/en not_active Expired - Fee Related
- 2007-03-30 WO PCT/US2007/008270 patent/WO2007117440A2/en not_active Ceased
- 2007-03-30 CA CA2647246A patent/CA2647246C/en not_active Expired - Fee Related
- 2007-03-30 JP JP2009503084A patent/JP2009532369A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weintraub et al. | Impulse control and related disorders in Parkinson's disease | |
| Wu et al. | Noninvasive brain stimulation for Parkinson’s disease and dystonia | |
| Burke | The neural basis of Charles Bonnet hallucinations: a hypothesis | |
| JP2007500757A5 (enExample) | ||
| JP2009506069A5 (enExample) | ||
| JP2019031502A5 (enExample) | ||
| EP1696905B1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| WO2004110389A3 (en) | Sigma ligands for neuronal regeneration and functional recovery | |
| WO2016210372A3 (en) | Methods to treat neurological diseases | |
| EP2279727A3 (en) | Nanoparticulate aripiprazole formulations | |
| JP2014505688A5 (enExample) | ||
| Verleger | Event-related EEG potential research in neurological patients | |
| CY1105507T1 (el) | Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες | |
| JP2011516588A5 (enExample) | ||
| CA3079194A1 (en) | Therapeutic agents for neurodegenerative diseases | |
| WO2010064248A3 (en) | Methods of diagnosing and treating motor neuron diseases | |
| JP2006515370A5 (enExample) | ||
| WO2007098020A3 (en) | Methods of screening patients for omega-3 fatty acid therapy | |
| EP4583862A1 (en) | Use of mdma for treatment of stress-related disorders | |
| JP2002535334A5 (enExample) | ||
| WO2003030836A3 (en) | Neuronal regeneration | |
| Velázquez-Pérez et al. | Spinocerebellar ataxia type 2 | |
| WO2011123842A9 (en) | Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain | |
| SE0004455D0 (sv) | Method for neuron regeneration in the central nervous system | |
| US10034848B2 (en) | Increase of protein synthesis ameliorates synaptopathy-related neurological disorders |